Holen Sie sich die Stockscreener-App
161.91
1.60%
-2.63
Handel nachbörslich:
162.00
0.09
+0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$164.54
Offen:
$165.58
24-Stunden-Volumen:
4.05M
Relative Volume:
0.91
Marktkapitalisierung:
$114.60B
Einnahmen:
$24.78B
Nettoeinkommen (Verlust:
$3.68B
KGV:
31.29
EPS:
5.1743
Netto-Cashflow:
$5.29B
1W Leistung:
-5.40%
1M Leistung:
-18.29%
6M Leistung:
-26.81%
1J Leistung:
-15.21%
1-Tages-Spanne:
$160.93
$166.28
1-Wochen-Bereich:
$160.93
$171.73
52-Wochen-Spanne:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
Masimo Corp stock (US5747951003): earnings, Danaher deal and what’s next for the medical-tech spec - AD HOC NEWS
Solid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen’s Large-Cap Stock Picks - Yahoo Finance
Danaher Masimo Deal Shifts Growth Outlook And Investor Focus - Yahoo Finance
DoorDash Inc stock (US2358511028): Q1 2026 profit beat keeps growth story in focus - AD HOC NEWS
Danaher Valuation Reset Highlights Recurring Revenues And Lean Operating Framework - Yahoo Finance
Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says - marketscreener.com
DHR Reinstated by RBC Capital -- Price Target Set at $200 - GuruFocus
Danaher Stock: Analyst Estimates & Ratings - Yahoo Finance
Danaher stock (US2358511028): spin-offs reshape the medtech group after latest quarterly numbers - AD HOC NEWS
Danaher (DHR) Receives Outperform Rating from RBC Capital with $200 Price Target - GuruFocus
RBC Capital assumes Danaher stock coverage with outperform rating - Investing.com UK
RBC Capital assumes Danaher stock coverage with outperform rating By Investing.com - Investing.com Nigeria
DoorDash Inc stock (US2358511028): investors weigh latest results and US food delivery outlook - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Jim Cramer Discusses the Performance of Danaher and Its Peers - Insider Monkey
Danaher stock (US2358511028): Shares decline amid four-day losing streak - AD HOC NEWS
The Escalator: Rx&O, Danaher, Ruder Finn and more - Medical Marketing and Media
DHR Technical Analysis | Trend, Signals & Chart Patterns | DANAHER CORP (NYSE:DHR) - ChartMill
Transcript : Danaher Corporation Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 11 - marketscreener.com
Is Danaher Corporation (DHR) A Good Stock To Buy Now? - Yahoo Finance
Jim Cramer’s Take on 5 Stocks: Home Depot, Procter & Gamble, and Danaher - Insider Monkey
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Danaher stock (US2358511028): Shares slide as institutional holdings shift - AD HOC NEWS
Jim Cramer Warns This Market Is Far More Brutal Than Dot-Com Bubble Era: 'The Difference Between Now And - Benzinga
Rainer Blair: Innovative Leader, Danaher Business System Champion, and President and Chief Executive Officer of Danaher Corporation - BBN Times
Danaher Corp. stock underperforms Monday when compared to competitors - MarketWatch
All eyes on Masimo earnings amid pending Danaher takeover - Investing.com
Danaher stock hits 52-week low at $170.19 - Investing.com
Danaher stock (US2358511028): Analyst consensus targets 40% upside amid mixed sentiment - AD HOC NEWS
DAP.DE Stock Price, Quote & Chart | DANAHER CORP (FRA:DAP) - ChartMill
Is Danaher (DHR) Pricing Look Interesting After Recent Life Sciences Portfolio Focus News - Yahoo Finance
Danaher Corp. stock (US2358511028): Shares near 52-week low after mixed Q1 2026 results and analyst - AD HOC NEWS
McGuire Investment Group, LLC's Danaher Corp(DHR) Holding History - GuruFocus
Danaher Corp. stock underperforms Friday when compared to competitors - MarketWatch
Danaher Corp. may be the smartest bet in biotech right now - MSN
IDBS brings BioPharma leaders together at flagship i3 2026 forum in Boston - Carroll County Mirror-Democrat
Danaher Corp. Stock (US2358511028): Analyst Downgrades and 52-Week Low Test - AD HOC NEWS
Pregnancy Detection Kits Market Analysis Report 2026 - GlobeNewswire Inc.
DHR Stock Price, Quote & Chart | DANAHER CORP (NYSE:DHR) - ChartMill
Danaher shareholders approve incentive plan and elect directors at annual meeting - Investing.com
Danaher (NYSE: DHR) investors approve incentive plan, pay and auditor - Stock Titan
Here’s What Morgan Stanley Thinks About Danaher Corporation (DHR) - Insider Monkey
Danaher to webcast CEO remarks from May 13 Las Vegas conference - Stock Titan
Danaher to Present at Bank of America Securities Healthcare Conference - marketscreener.com
Agilent Taps Danaher Deal Lawyer As Chief Legal Officer - Law360
Swedbank AB Raises Stock Holdings in Danaher Corporation $DHR - MarketBeat
Danaher Corpdeclares quarterly cash dividend of $0.40 per share payable July 31, 2026 - marketscreener.com
Masimo Corp. stockholders adopted Danaher merger agreement May 1 - MLex
Danaher to acquire Masimo (NASDAQ: MASI) in $180 per share cash deal - Stock Titan
Danaher declares $0.40 quarterly dividend payable July 31 - Investing.com
Danaher declares $0.40 quarterly dividend payable July 31 By Investing.com - Investing.com Canada
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):